öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£º³Ìº£Áè
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º197

ËùÊôԺУ£º´óÁ¬Ò½¿Æ´óѧ
ËùÊôԺϵ£ºµÚ¶þÁÙ´²Ñ§Ôº
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÉúÎﻯѧÓë·Ö×ÓÉúÎïѧ
Ñо¿ÁìÓò£º 1.°©Ö¢Ï¸°ûÐźŴ«µ¼Í¨Â·ÔÚ°©Ö¢·¢Éú¡¢·¢Õ¹ÖеÄ×÷ÓúͷÖ×Ó»úÖÆ£¬×ÛºÏÓ¦ÓÃÉúÎﻯѧÓë·Ö×ÓÉúÎïѧ¡¢... [Õ¹¿ª]


Ñо¿ÁìÓò£º 1.°©Ö¢Ï¸°ûÐźŴ«µ¼Í¨Â·ÔÚ°©Ö¢·¢Éú¡¢·¢Õ¹ÖеÄ×÷ÓúͷÖ×Ó»úÖÆ£¬×ÛºÏÓ¦ÓÃÉúÎﻯѧÓë·Ö×ÓÉúÎïѧ¡¢Ï¸°ûÉúÎïѧ¡¢»ùÒò×éѧºÍµ°°×ÖÊ×éѧ¡¢ÒÔ¼°»ùÒò¹¤³ÌСÊóÄ£ÐÍ£¬Ñ°ÕÒÇý¶¯Ö×Áö·¢ÉúºÍϸ°ûÐźŴ«µ¼Òì³£µÄ¹Ø¼üÖ°©»ùÒò»òÒò×Ó£¬²¢ÒÔ´ËΪ°Ðµã£¬Éè¼Æ·Ö×Ó°ÐÏòÒ©ÎïºÍÖÎÁÆ·½°¸£¬ÎªÁÙ´²ÖÎÁÆÌṩһ¶¨µÄ°ïÖú¡£2.°©Ö¢¸´·¢¡¢×ªÒÆ¡¢ÄÍÒ©µÄ·Ö×Ó»úÖÆ£¬½¨Á¢ÄÍҩϸ°ûÖê¡¢»ùÒò×éÎĿ⹦ÄÜ»ñµÃÐԺ͹¦ÄÜȱʧÐÔ£¨ÈçRNA¸ÉÈÅ¡¢CRISPR/Cas9»ùÒòÇóý£©¸ßͨÁ¿É¸Ñ¡£¬Ñ°ÕÒµ¼ÖÂÖ×Áö¸´·¢ºÍÄÍÒ©µÄ¹Ø¼ü»ùÒò¡¢·Ö×Ó±ê¼ÇÎïÒÔ¼°ÓëÒ©ÎïÖÎÁƺϳÉÖÂËÀ»ùÒò/Òò×Ó¡£ÔÚ´Ë»ù´¡ÉÏ£¬ÎÒÃǽ«Éè¼ÆÕë¶Ô¸ÃÖÖÖ×ÁöµÄ°ÐÏòÁÆ·¨»òÁªºÏ°ÐÏòÖÎÁÆ·½°¸£¬²¢Í¨¹ýÖ×ÁöÒÅ´«¹¤³ÌСÊóÄ£ÐÍ¡¢ÁÙ´²²¡ÈËÀ´Ô´µÄÖ×ÁöÑù±¾ÒìÌåÒÆֲСÊóÄ£ÐͽøÐÐÁÙ´²Ç°ÊÔÑéÀ´È·Ö¤¸ÃÖÎÁÆ·½°¸µÄÓÐЧÐÔ£¬ÎªÌá¸ßÁÙ´²Ö×Áö»¼ÕßÖÎÓúÂÊÌṩ°ïÖú¡£3.Ö×ÁöµÄÃâÒßÖÎÁÆ£¬Í¨¹ýÒÅ´«¸ÄÔìTϸ°ûÊÜÌå,ʹÆä±í´ïÒ»ÖÖÈ˹¤°ÐÏòÖ×Áöϸ°ûµÄÊÜÌå,ÕâÑù¾Í¿Éʹ»¼ÕßµÄTϸ°ûÄܹ»Ê¶±ðÖ×Áö¿¹Ô­£¬´Ó¶øɱËÀÖ×Áöϸ°û£»Í¬Ê±ÎÒÃÇÒ²ÕýÔÚÑз¢Ö×ÁöÒßÃçºÍϸ°ûÖÜÆÚ¼ì²éµãÒÖÖƼÁ£¬ÎªÉè¼ÆеÄÖ×ÁöÃâÒßÖÎÁÆ·½°¸ÌṩеÄ˼·¡£ [ÊÕÆð]




ͨѶ·½Ê½ :
µç×ÓÓʼþ£ºhailingcheng_dmu@163.com


¸öÈ˼òÊö :
³Ìº£Áè½ÌÊÚ£¬´óÁ¬Ò½¿Æ´óѧ¸½ÊôµÚ¶þÒ½ÔºÖ×ÁöÑо¿ËùËù³¤¡¢¿ÆÑÐÖÐÐĸ±Ö÷ÈΣ¬²©Ê¿Éúµ¼Ê¦£¬Ö÷ÒªÑо¿Ï¸°ûÐźÅϸ°ûÐźŴ«µ¼Í¨Â·¡¢Ö×ÁöµÄ·Ö×Ó°ÐÏòÖÎÁƼ°ÃâÒßÖÎÁÆ
ÈÙÓþ½±Ïî:ÁÉÄþÊ¡µÚ¶þÅú¡°Ê®°Ùǧ¸ß¶ËÈ˲ÅÒý½ø¹¤³Ì¡±Ç§È˲ã´ÎÈËÑ¡£¨2015£©ÁÉÄþÊ¡ÁôѧÈËÔ±¿Æ¼¼»î¶¯ÏîÄ¿ÔñÓÅ×ÊÖúÏîÄ¿£¨2015£©´óÁ¬Ò½¿Æ´óѧ¸½ÊôµÚ¶þÒ½ÔºÖÐÇàÄêѧ¿Æ¾«Ó¢£¨2015£©ÁÉÄþÊ¡ÉúÎïÁìÓòÅʵÇѧÕßÖ§³Ö¼Æ»®£¨2014£©ÃÀ¹úSusan G. KomanÈéÏÙ°©°©Ö¢»ù½ð»áÑо¿»ù½ð£¨2012-2014£©ÃÀ¹ú¹þ·ð´óѧҽѧԺFriends°©Ö¢Ñо¿»ù½ð£¨2011-2012£©ÃÀ¹ú¹þ·ð´óѧҽѧԺŮÐÔ°©Ö¢Ñо¿»ù½ð£¨2010 - 2011£©

¿ÆÑй¤×÷ :
ÔÚÑÐÏîÄ¿1¡¢¡°PIK3CA »ùÒòÍ»±äÔÚ×Ó¹¬ÄÚĤ°©·¢Éú·¢Õ¹ÖеÄ×÷Óü°·Ö×Ó°ÐÏòÖÎÁÆ¡±¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£¬2015-2018£¬70ÍòÔª£¬Ö÷³Ö
2¡¢¡°Å®ÐÔÖ×ÁöµÄ·Ö×Ó°ÐÏòÖÎÁÆ¡±£¬ÁÉÄþÊ¡ÅʵÇѧÕßÖ§³Ö¼Æ»®£¬2015-2017Ä꣬150ÍòÔª£¬Ö÷³Ö
´ú±íÎÄÕÂ1¡¢Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget, 2016 Mar 157(11):13153-66. IF:5.008 ͨѶ×÷Õß
2¡¢PIK3CAH1047R and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene, 2016 Jun 935(23):2961-70.. IF: 8.459. ͨѶ×÷Õß
3¡¢Chemopreventive effects of aspirin at a glance. Biochimica et Biophysica Acta, 2015, 1855:254-263. IF: 7.845.ͨѶ×÷Õß4¡¢Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells. Curr Mol Med, 2015.15(5),475-86. IF: 3.69. ͨѶ×÷Õß
5¡¢A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 is highly responsive to mTOR inhibition. Cancer Res, 2014, 74(1): 15-23. ËûÒý´ÎÊý£º20£¬IF: 9.329. ͨѶ×÷Õß
6¡¢Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and -independent mechanisms. Nature Medicine, 2011, 17(9):1116-20. IF: 28.054.µÚÒ»×÷Õß
7¡¢SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis.Science Signaling, 2009, 2(80): ra35. IF: 6.337. µÚÒ»×÷Õß
8¡¢Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov, 2009, 8(8):627-644. IF: 37.231. µÚ¶þ×÷Õß
9¡¢The Essential WD Repeat Protein Swd2 Has Dual Functions in RNA Polymerase II Transcription Termination and Lysine 4 Methylation of Histone H3. Mol. Cell Biol, 2004, 24: 2932-2943. IF: 5.036. µÚÒ»×÷Õß
10¡¢Rat glutathione S-transferase M4-4: an isoenzyme with unique structural features including a redox-reactive cysteine-115 residue that forms mixed disulphides with glutathione. Biochem J, 2001, 356:403-414. IF: 4.779.µÚÒ»×÷Õß

½ÌÓý±³¾° :
2014 - ÖÁ½ñ ´óÁ¬Ò½¿Æ´óѧ¸½ÊôµÚ¶þÒ½Ôº Ö×ÁöÑо¿ËùËù³¤ ¿ÆÑÐÖÐÐĸ±Ö÷ÈΣ»2010 ¨C 2014 ÃÀ¹ú¹þ·ð´óѧҽѧԺ Dana-Farber°©Ö¢Ñо¿Ëù ¿Æѧ¼Ò£» ÃÀ¹ú¹þ·ð´óѧҽѧԺ Brigham and WomenÒ½Ôº ½²Ê¦£»2005 - 2009 ÃÀ¹ú¹þ·ð´óѧҽѧԺ Dana-Farber°©Ö¢Ñо¿Ëù ²©Ê¿ºó£»2005 ÃÀ¹úËþ·ò´Ä´óѧ ÒÅ´«Ñ§ ²©Ê¿£»2000 ÃÀ¹ú±öÎ÷·¨ÄáÑÇÖÝÖÝÁ¢´óѧ ÒÅ´«Ñ§ ˶ʿ£»1995 ¸´µ©´óѧ ÉúÃü¿ÆѧԺ ѧʿ¡£